GET DAILY SIGNALSWhy Is InterCure Ltd. (INCR) Stock Down -5.48% Today?
Key Takeaways
- INCR shares fell 5.48% to $3.28, down from the prior session's close of $3.47.
- The decline reversed the previous session's 5.31% gain, suggesting profit-taking in a thinly traded, volatile micro-cap.
- No single company-specific headline drove the move; uncertainty ahead of upcoming third-quarter earnings is weighing on sentiment.
- The stock remains below its 50-day and 200-day moving averages, with technical indicators in oversold territory.
- Investors are watching the upcoming quarterly results, expected in mid-November, along with continued execution in the German market.
- You can find more information on Price Targets, Earnings, and Forecast for this ticker on dedicated pages.
- Explore Trending AI Robots to discover AI-driven trading strategies currently tracking this and other stocks.
Opening Summary
InterCure Ltd. (INCR), an Israeli producer and distributor of pharmaceutical-grade medical cannabis operating primarily under the Canndoc brand, traded lower on Monday. Shares were down 5.48% to $3.28, compared with the prior session's closing price of $3.47. The decline erased the stock's advance from the previous trading day and reflects a pullback in a low-float, thinly traded equity rather than a response to any single breaking headline. Market participants pointed to profit-taking and positioning uncertainty ahead of the company's next quarterly earnings report as the primary near-term drivers.
Profit-Taking After a Volatile Run
The drop follows a 5.31% gain in the previous session, making Monday's move a classic mean-reversion trade. INCR has been prone to sharp swings since its 1-for-5 reverse stock split in August 2026, a move implemented to regain compliance with Nasdaq's minimum bid price requirement. The company confirmed in early September that it had regained compliance, but the share-count adjustment has left the stock with a reduced float and elevated sensitivity to relatively small shifts in order flow. With daily trading volume frequently modest, even routine selling pressure can translate into outsized percentage moves.
Earnings Uncertainty Ahead of Quarterly Results
A significant source of caution is the company's upcoming third-quarter earnings release, expected in mid-November. INCR has posted consecutive periods of revenue growth and positive adjusted EBITDA, yet it has remained unprofitable on a net basis, and prior reports have been met with selling pressure when results failed to exceed elevated expectations. Investors appear reluctant to hold positions into the print, particularly given the company's mixed margin trajectory and the heavy reliance on a handful of international growth initiatives still in early stages.
Persistent Technical and Fundamental Headwinds
The decline also reflects a broader technical picture. INCR is trading below both its 50-day and 200-day moving averages, and its relative strength index has hovered near oversold levels. Longer term, the stock has shed roughly half its value over the past 52 weeks. While the company finalized a NIS 230 million (approximately US$77 million) settlement for war-related indirect damages in August and has secured additional financing, concerns about share dilution and sustained net losses continue to temper investor enthusiasm. A higher-than-usual trading session on the prior day also suggests some of Monday's weakness reflects unwinding of short-term speculative positions.
Market Context and Trading Activity
The move in INCR did not coincide with a clearly defined sector catalyst, and the stock's small size means it often trades on its own liquidity dynamics rather than in lockstep with larger cannabis peers or broad equity indices. Volume in recent sessions has at times run well above the stock's roughly 7,000-share daily average, underscoring the elevated turnover accompanying its recent volatility. The pullback pushed the shares further below key technical levels that had acted as near-term reference points, leaving limited visible support in the immediate range.
What Comes Next for INCR
The primary event on the horizon is the company's third-quarter earnings report, expected in the coming weeks. Traders will be watching for evidence of sustained revenue momentum in Israel and early traction in Germany, where INCR has been expanding its distribution of GMP-certified medical cannabis products. Margin performance, cash generation, and any updates on the rehabilitation of its Nir Oz facility will also be closely scrutinized. Risks include continued net losses, potential future capital raises that could dilute existing shareholders, and the inherent regulatory and macro uncertainty surrounding the global medical cannabis market. Until fundamentals or fresh catalysts provide clearer direction, the stock is likely to remain volatile.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to consider. Explore the Trending AI Robots page to see which automated strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INCR sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for INCR moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCR as a result. In 88 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for INCR turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for INCR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
INCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.113) is normal, around the industry mean (7.271). P/E Ratio (-2.410) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.640) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. INCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of outsourced clinical development and commercialization services to biopharmaceutical companies
Industry PharmaceuticalsGeneric
Advertisement